RATIONALE: Benzodiazepines continue to be widely used for the treatment of anxiety, but it is well known that benzodiazepines have undesirable side effects, including sedation, ataxia, cognitive deficits and the risk of addiction and abuse. CRF(1) receptor antagonists are being developed as potential novel anxiolytics, but while CRF(1) receptor antagonists seem to have a better side-effect profile than benzodiazepines with respect to sedation and ataxia, the effects of CRF(1) receptor antagonists on cognitive function have not been well characterized. It is somewhat surprising that the potential cognitive effects of CRF(1) receptor antagonists have not been more fully characterized since there is some evidence to suggest that these compounds may impair cognitive function. OBJECTIVE: The Morris water maze and the delayed non-matching to position test are sensitive tests of a range of cognitive functions, including spatial learning, attention and short-term memory, so the objective of the present experiments was to assess the effects of benzodiazepines and CRF(1) receptor antagonists in these tests. RESULTS: The benzodiazepines chlordiazepoxide and alprazolam disrupted performance in the Morris water maze and delayed non-matching to position at doses close to their therapeutic, anxiolytic doses. In contrast, the CRF(1) receptor antagonists DMP-904 and DMP-696 produced little or no impairment in the Morris water maze or delayed non-matching to position test even at doses 10-fold higher than were necessary to produce anxiolytic effects. CONCLUSIONS: The results of the present experiments suggest that, with respect to their effects on cognitive functions, CRF(1) receptor antagonists seem to have a wider therapeutic index than benzodiazepines.
RATIONALE: Benzodiazepines continue to be widely used for the treatment of anxiety, but it is well known that benzodiazepines have undesirable side effects, including sedation, ataxia, cognitive deficits and the risk of addiction and abuse. CRF(1) receptor antagonists are being developed as potential novel anxiolytics, but while CRF(1) receptor antagonists seem to have a better side-effect profile than benzodiazepines with respect to sedation and ataxia, the effects of CRF(1) receptor antagonists on cognitive function have not been well characterized. It is somewhat surprising that the potential cognitive effects of CRF(1) receptor antagonists have not been more fully characterized since there is some evidence to suggest that these compounds may impair cognitive function. OBJECTIVE: The Morris water maze and the delayed non-matching to position test are sensitive tests of a range of cognitive functions, including spatial learning, attention and short-term memory, so the objective of the present experiments was to assess the effects of benzodiazepines and CRF(1) receptor antagonists in these tests. RESULTS: The benzodiazepineschlordiazepoxide and alprazolam disrupted performance in the Morris water maze and delayed non-matching to position at doses close to their therapeutic, anxiolytic doses. In contrast, the CRF(1) receptor antagonists DMP-904 and DMP-696 produced little or no impairment in the Morris water maze or delayed non-matching to position test even at doses 10-fold higher than were necessary to produce anxiolytic effects. CONCLUSIONS: The results of the present experiments suggest that, with respect to their effects on cognitive functions, CRF(1) receptor antagonists seem to have a wider therapeutic index than benzodiazepines.
Authors: P J Whitehouse; W W Vale; R M Zweig; H S Singer; R Mayeux; M J Kuhar; D L Price; E B De Souza Journal: Neurology Date: 1987-06 Impact factor: 9.910
Authors: S C Heinrichs; M P Stenzel-Poore; L H Gold; E Battenberg; F E Bloom; G F Koob; W W Vale; E M Pich Journal: Neuroscience Date: 1996-09 Impact factor: 3.590
Authors: G W Smith; J M Aubry; F Dellu; A Contarino; L M Bilezikjian; L H Gold; R Chen; Y Marchuk; C Hauser; C A Bentley; P E Sawchenko; G F Koob; W Vale; K F Lee Journal: Neuron Date: 1998-06 Impact factor: 17.173
Authors: Clare J Wilhelm; Aaron Murphy-Crews; Daniel J Menasco; Marilyn S Huckans; Jennifer M Loftis Journal: Neuropharmacology Date: 2011-08-04 Impact factor: 5.250
Authors: Xiao-Dong Wang; Yuncai Chen; Miriam Wolf; Klaus V Wagner; Claudia Liebl; Sebastian H Scharf; Daniela Harbich; Bianca Mayer; Wolfgang Wurst; Florian Holsboer; Jan M Deussing; Tallie Z Baram; Marianne B Müller; Mathias V Schmidt Journal: Neurobiol Dis Date: 2011-02-03 Impact factor: 5.996
Authors: Ammar L Ujjainwala; Connor D Courtney; Natalia M Wojnowski; Justin S Rhodes; Catherine A Christian Journal: J Neurosci Res Date: 2019-01-25 Impact factor: 4.164